- Home
- SEPN vs ITOS Comparison
SEPN vs ITOS Comparison
Compare SEPN & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEPN
- ITOS
- Stock Information
- Founded
- SEPN 2022
- ITOS 2011
- Country
- SEPN United States
- ITOS United States
- Employees
- SEPN N/A
- ITOS N/A
- Industry
- SEPN
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SEPN
- ITOS Health Care
- Exchange
- SEPN NYSE
- ITOS Nasdaq
- Market Cap
- SEPN 453.2M
- ITOS 381.2M
- IPO Year
- SEPN 2024
- ITOS 2020
- Fundamental
- Price
- SEPN $11.76
- ITOS $10.26
- Analyst Decision
- SEPN Strong Buy
- ITOS Hold
- Analyst Count
- SEPN 5
- ITOS 6
- Target Price
- SEPN $26.75
- ITOS $10.60
- AVG Volume (30 Days)
- SEPN 443.6K
- ITOS 764.9K
- Earning Date
- SEPN 08-15-2025
- ITOS 08-07-2025
- Dividend Yield
- SEPN N/A
- ITOS N/A
- EPS Growth
- SEPN N/A
- ITOS N/A
- EPS
- SEPN N/A
- ITOS N/A
- Revenue
- SEPN $977,000.00
- ITOS $35,000,000.00
- Revenue This Year
- SEPN N/A
- ITOS N/A
- Revenue Next Year
- SEPN $526.96
- ITOS N/A
- P/E Ratio
- SEPN N/A
- ITOS N/A
- Revenue Growth
- SEPN 108.76
- ITOS 177.89
- 52 Week Low
- SEPN $4.17
- ITOS $4.80
- 52 Week High
- SEPN $28.99
- ITOS $18.13
- Technical
- Relative Strength Index (RSI)
- SEPN N/A
- ITOS 66.97
- Support Level
- SEPN N/A
- ITOS $10.05
- Resistance Level
- SEPN N/A
- ITOS $10.21
- Average True Range (ATR)
- SEPN 0.00
- ITOS 0.13
- MACD
- SEPN 0.00
- ITOS -0.06
- Stochastic Oscillator
- SEPN 0.00
- ITOS 81.48
About SEPN SEPTERNA INC
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.